Edit
XenoPort, Inc.
http://www.xenoport.com/Last activity: 17.07.2021
Active - Reference to Azurity Pharmaceuticals
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
Location: United States
Employees: 201-500
Total raised: $20M
Founded date: 1999
Investors 2
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Frazier Li... | frazierls.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.11.2012 | - | $20M | - |
Mentions in press and media 4
| Date | Title | Description |
| 07.06.2012 | GSK gets FDA approval on Horizant to treat post-shingles pain | The first commercial sales of Horizant for PHN will trigger a $10 million milestone payment to XenoPort (NASDAQ:XNPT), the Santa Clara, California company that discovered Horizant and co-developed the drug with GSK. The companies entered th... |
| 24.02.2012 | GSK sues partner XenoPort over marketing allegations on RLS drug | GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, entered a partnership with XenoPort in 2007 to develop and commercialize a compound discovered by XenoPort that would eventually become the drug Horizant. The d... |
| - | GSK sues partner XenoPort over marketing allegations on RLS drug | GlaxoSmithKline (NYSE:GSK) is pushing back against drug partner XenoPort (NASDAQ:XNPT) over claims that GSK is not doing enough to sell the restless leg syndrome treatment they jointly developed. The British pharma giant has asked a federal... |
| - | GSK gets FDA approval on Horizant to treat post-shingles pain | GlaxoSmithKline‘s (NYSE:GSK) restless leg syndrome drug Horizant has received U.S. approval for the new indication of treating pain following shingles. The condition, called postherpetic neuralgia (PHN), is a nerve pain syndrome that follow... |